Authorization

BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (a??NDAa??) submission to U.S. Food and Drug Administration (a??FDAa??) planned for Q1 2021
Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patientsInitiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab (a??KEYTRUDAa??) to include patients with castrate-resistant prostate cancer (a??CRPCa??)Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceedsCompany to host conference call today at 8:30 a.m. ET
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930